HCW Biologics (HCWB)

• Market cap: $5.32M
• 1 day: -7.08%
• 5 days: -8.8%
• 1 month: -45.28%
• 3 months: -63.18%
• 6 months: -72.68%
• Year to date: -89.12%
• 1 year: -90.34%
• 5 years: -99.22%
• 10 years: -99.22%
• Sector: Healthcare
• Industry: Biotechnology

About: HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

Employees: 36